Leczenie posocznicy.

Liczba wypowiedzi w tym wątku: 4

1. Data: 2004-02-12 12:20:09

Temat: Leczenie posocznicy.
Od: "Zbigniew" <t...@p...com> szukaj wiadomości tego autora

Wczoraj (to jest w środę 11.02) była informacja w TV
na temat nowej metody leczenia posocznicy.
Usłyszałem tylko fragment (coś o białku).

Czy ktoś z grupowiczów może przybliżyć temat ?

› Pokaż wiadomość z nagłówkami

Do góry

Zobacz także

2. Data: 2004-02-12 14:37:23

Temat: Re: Leczenie posocznicy.
Od: a...@o...pl szukaj wiadomości tego autora

hehe, masz jakies nie za swieze informacje, o leczeniu posocznicy bialkiem C
mowi sie juz dosc dlugo, jest skuteczne, ale niestety kosztowne... nie wiem na
tyle duzo o tej metodze by zaspokoic Twoja ciekawosc, poszukaj na stronie
www.sepsa.pl
pozdrawiam, aga.

--
Wysłano z serwisu OnetNiusy: http://niusy.onet.pl

› Pokaż wiadomość z nagłówkami

Do góry

3. Data: 2004-02-12 19:27:48

Temat: Re: Leczenie posocznicy.
Od: "deBerg" <d...@o...pl> szukaj wiadomości tego autora

Kosztowne - xigris to ok 46 000 pln za op :) Ale oddzielnie finansowane z
nfz i zlecane po uzyskaniu zgody konsultanta krajowego (chyba) :)

› Pokaż wiadomość z nagłówkami

Do góry

4. Data: 2004-02-12 21:15:47

Temat: Re: Leczenie posocznicy.
Od: Piotr Kasztelowicz <p...@r...am.torun.pl> szukaj wiadomości tego autora

On Thu, 12 Feb 2004 a...@o...pl wrote:

> hehe, masz jakies nie za swieze informacje, o leczeniu posocznicy bialkiem C

DROTRECOGIN ALFA HAS LIMITED USEFULNESS IN THE TREATMENT OF SEVERE SEPSIS
IN
GERIATRIC PATIENTS
[Chest 2003 Scientific Highlights: Abstracts of Original Investigations
and
Case Reports: October 25-30 Orlando, Florida: Poster Presentations *
Wednesday, October 29, 2003: Sepsis, 12:30 PM - 2:00 PM]
Khan, Tehmina MD[degrees]; Kupfer, Yizhak MD; Pascal, William MD;
Tessler,
Sidney MD
Maimonides Medical Center, Brooklyn, NY

----------------------------------------------

INTRODUCTION: The PROWESS trial demonstrated that drotrecogin Alfa (DA)
reduced mortality in patients with severe sepsis and septic shock. The
trial, however, excluded many patients, especially those with an
increased
risk of bleeding. Evidence-based medicine dictates that the results of a
trial be applied only to patients that are similar to the group studied.
We
therefore, prospectively studied the utility of DA in geriatric patients
with severe sepsis.
METHODS: All patients over the age of 70 with severe sepsis, assessed by
the
critical care service were evaluated for administration of DA. Only
patients
with APACHE II scores of 25 or greater and who did not meet any of the
PROWESS exclusion criteria were given DA. The reason for not
administering
DA was recorded.
RESULTS: Between January 1 and April 30, 2003, 158 patients were
evaluated.
One hundred fifty seven patients (99.4%) were not eligible for DA
administration. Ninety-nine patients had low APACHE II scores (63%).
Eighty-five patients (54%) had active internal bleeding predominantly
from
the GI tract. Fifty five patients (35%) required dialysis, 15 (9.5%) had
GI
bleeding within 6 weeks, 8 (5%) were concurrently receiving heparin, 23
(15%) recently received platelet inhibitors, 6 (4%) had severe
thrombocytopenia, 18 (11.4%) had a poor life expectancy, 5 (3%) had
cerebral
complications and 4 (3%) had severe hepatic failure. Many patients had
more
than one contraindication to DA. One patient received DA and was
discharged
from the hospital.
CONCLUSIONS: DA has limited utility in the treatment of severe sepsis in
geriatric patients. Further trials are required to accurately define all
the
patients with sepsis that would potentially benefit from DA.

w Polsce preparat jest juz dostepny i stosowany w wybranych
osrodkach klinicznych

P.

Piotr Kasztelowicz <P...@r...am.torun.pl>
*Sun Classic OpenBSD installation - to make an old computer young!
We are open on Open(BSD)!-> http://renata.am.torun.pl*
http://www.am.torun.pl/~pekasz